Blue Jet Healthcare Limited reported its unaudited financial results for the third quarter ended December 31, 2025, showing a notable decline in quarterly performance compared to the previous year. The pharmaceutical manufacturing company's Board of Directors approved these results during their meeting held on February 13, 2026.

Financial Performance Overview

The company's Q3FY26 results reflected challenging market conditions with significant year-on-year declines in key financial metrics:

Nine-Month Performance Analysis

Despite the quarterly challenges, the nine-month performance for the period ended December 31, 2025, showed more stability with modest growth in revenue:

Expense Structure and Operational Metrics

The company's expense management during Q3FY26 showed mixed results. Total expenses for the quarter stood at ₹1,518.46 million compared to ₹1,991.29 million in Q3FY25, representing a 23.7% decrease. Key expense components included:

• Cost of materials consumed: ₹789.32 million (down from ₹1,712.44 million)
• Employee benefits expense: ₹190.72 million (up from ₹148.25 million)
• Other expenses: ₹336.03 million (down from ₹351.23 million)
• Finance costs: ₹3.39 million (up from ₹0.16 million)

Investor Communication and Conference Call

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company announced an Analysts/Investors Presentation on the Financial Results for the quarter and nine months ended December 31, 2025. The presentation was scheduled for February 13, 2026, the same day as the Board meeting.

Following the earnings announcement, Blue Jet Healthcare conducted a conference call to discuss the financial results. In compliance with SEBI regulations, the company made the audio recording of this conference call available on its website at https://bluejethealthcare.com/investor-presentation/ .

Business Operations and Segment Information

Blue Jet Healthcare operates as a single reportable business segment focused on manufacturing artificial sweeteners, contrast media intermediates, pharmaceutical intermediates, and APIs used in pharmaceutical and healthcare products. The company maintains three manufacturing units located in Shahad, Ambernath, and Mahad in Maharashtra.

Corporate Governance and Compliance

The financial results were reviewed by the company's Audit Committee and subsequently approved by the Board of Directors. KKC & Associates LLP, the company's statutory auditors, conducted a limited review of the unaudited financial results in accordance with applicable auditing standards. The company maintains a paid-up equity share capital of ₹346.93 million with a face value of ₹2 per share, remaining unchanged from the previous periods.

Blue Jet Healthcare Limited has scheduled an analyst and investor conference call to discuss its financial performance for the third quarter and nine months of fiscal year 2026. The pharmaceutical company announced the earnings call through a regulatory filing under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Earnings Call Details

The conference call is scheduled to discuss the company's unaudited standalone financial results for the quarter and nine months ended December 31, 2025. Company Secretary and Compliance Officer Sweta Poddar signed the regulatory intimation on February 6, 2026.

Management Participation

The earnings call will feature key members of Blue Jet Healthcare's senior management team who will present the financial results and address questions from analysts and investors.

Company Profile

Blue Jet Healthcare Limited operates as a specialty pharmaceutical and healthcare ingredient company under a contract development and manufacturing organization (CDMO) business model. The company has developed specialized chemistry capabilities in two key areas: contrast media intermediates and high-intensity sweeteners.

The company has established long-term relationships with innovator and multinational generic pharmaceutical companies, supported by multi-year contracts. Blue Jet Healthcare supplies critical starting intermediates and advanced intermediates to three of the world's largest contrast media manufacturers, including GE Healthcare, Guerbet, and Bracco. Additionally, the company provides high-intensity sweeteners to multinational companies such as Colgate Palmolive India Limited and Unilever.

Contact Information

For further details regarding the earnings call, stakeholders can contact Company Secretary Sweta Poddar at companysecretary@bluejethealthcare.com . Investor relations support is provided by EY Investor Relations through Diwakar Pingle and Kunal Bhoite. Participants are advised to dial in 10 minutes before the scheduled call time.